Biotechnology company Cajal Neuroscience launched from stealth and raised USD 96 million in a Series A funding round led by The Column Group and Lux Capital, with participation from other investors, including Bristol Myers Squibb.
The new funds will be used towards the company’s target and drug discovery development efforts.
Cajal Neuroscience focuses on developing drugs through target discoveries to treat patients with neurodegenerative diseases (affecting nerve cells in the brain) such as Parkinson's and Alzheimer's disease. Its proprietary platform combines multi-omics, functional genomics, and microscopy to identify these new neurodegeneration targets.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.